Latest Period
Q2 2026
Security Snapshot
Protalix BioTherapeutics, Inc. - Common Stock (PLX) Institutional Ownership
CUSIP: 74365A309
13F Institutional Holders and Ownership History from Q4 2019 to Q2 2026
Institutions Reporting
101
Shares (Excl. Options)
14,460,390
Price
$2.33
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- PLX on NYSE
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 14,460,390
- Total 13F value
- $33,690,744
- Portfolio coverage rank
- 0%
- Share change
- -2,392,950
- Value change
- -$4,749,168
- Number of holders
- 101
- Shares outstanding
- 80,610,558
- SEC-reported price per share
- $2.27
- Insider filing price
- $2.27
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- PLX - Protalix BioTherapeutics, Inc. - Common Stock is tracked under CUSIP 74365A309.
- 101 institutions reported positions in Q2 2026.
- 2 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 100 to 101 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $36,572,629 to $33,690,744.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 101 institutions filings for Q2 2026.
Security key
74365A309
Latest holder period
Q2 2026
13F holders
101
13D/G owners
2
CIK / CUSIP context first
Open Q2 2026 holders
PLX full holder history
Protalix BioTherapeutics, Inc. SEC filings
Protalix BioTherapeutics, Inc. company facts
Protalix BioTherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 74365A309:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
2
Security
PLX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5% | $9,428,694 | 4,046,650 | BlackRock, Inc. | 30 Jun 2026 | |||
| MAK Capital Fund LP | 4.5% | -22% | $11,355,147 | -$3,244,593 | 3,616,289 | -22% | MAK Capital Fund LP | 24 Mar 2026 |
As of 30 Jun 2026, 101 institutional investors reported holding 14,460,390 shares of Protalix BioTherapeutics, Inc. - Common Stock (PLX). This represents 18% of the company’s total 80,610,558 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
16%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 5% | 4,046,650 | +12% | 0% | $9,428,694 |
| RENAISSANCE TECHNOLOGIES LLC | 1.4% | 1,096,000 | -11% | 0% | $2,553,680 |
| STATE STREET CORP | 1.2% | 983,582 | +1.1% | 0% | $2,291,746 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.2% | 979,995 | +13% | 0% | $2,283,388 |
| NORTHERN TRUST CORP | 1.1% | 922,340 | +4.2% | 0% | $2,149,053 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.63% | 510,639 | +18% | 0% | $1,189,789 |
| Stratos Wealth Partners, LTD. | 0.62% | 500,000 | 0% | 0.01% | $1,165,000 |
| DIMENSIONAL FUND ADVISORS LP | 0.61% | 493,424 | +66% | 0% | $1,149,868 |
| GOLDMAN SACHS GROUP INC | 0.59% | 475,922 | +89% | 0% | $1,108,899 |
| MARSHALL WACE, LLP | 0.56% | 452,757 | 0% | $1,054,925 | |
| CITADEL ADVISORS LLC | 0.41% | 334,227 | 0% | $778,749 | |
| STRS OHIO | 0.37% | 296,100 | 0% | $689,913 | |
| Bank of New York Mellon Corp | 0.29% | 232,992 | +6.2% | 0% | $542,871 |
| Main Street Financial Solutions, LLC | 0.27% | 214,100 | 0% | 0.03% | $498,853 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.23% | 189,100 | 0% | 0.01% | $440,603 |
| Hillsdale Investment Management Inc. | 0.23% | 185,711 | 0.01% | $432,707 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.22% | 180,381 | +13% | 0% | $420,288 |
| MILLENNIUM MANAGEMENT LLC | 0.21% | 171,535 | 0% | $399,677 | |
| AQR CAPITAL MANAGEMENT LLC | 0.21% | 167,826 | +450% | 0% | $391,035 |
| LAZARD ASSET MANAGEMENT LLC | 0.21% | 165,561 | +91% | 0% | $385,757 |
| UBS Group AG | 0.17% | 138,646 | -48% | 0% | $323,045 |
| JPMORGAN CHASE & CO | 0.16% | 132,991 | +320% | 0% | $312,529 |
| Nuveen, LLC | 0.11% | 90,188 | 0% | 0% | $210,138 |
| DEUTSCHE BANK AG\ | 0.1% | 77,537 | +3.4% | 0% | $180,661 |
| VANGUARD FIDUCIARY TRUST CO | 0.09% | 70,277 | +11% | 0% | $163,745 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
27
Latest
Q2 2026
Rows shown
1-25 of 27
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 14,460,390 | $33,690,744 | -$4,749,168 | $2.33 | 101 |
| 2026 Q1 | 16,863,462 | $36,572,629 | +$4,420,350 | $2.17 | 100 |
| 2025 Q4 | 14,904,284 | $26,832,150 | +$1,854,272 | $1.80 | 82 |
| 2025 Q3 | 13,927,352 | $30,914,125 | +$4,618,112 | $2.22 | 76 |
| 2025 Q2 | 11,908,531 | $17,628,861 | +$1,905,095 | $1.48 | 62 |
| 2025 Q1 | 8,186,092 | $20,953,817 | +$9,615,818 | $2.56 | 63 |
| 2024 Q4 | 4,467,337 | $8,398,680 | +$2,201,784 | $1.88 | 46 |
| 2024 Q3 | 3,383,529 | $3,451,053 | -$2,253,845 | $1.02 | 43 |
| 2024 Q2 | 5,625,789 | $6,582,396 | -$4,774,740 | $1.17 | 64 |
| 2024 Q1 | 9,445,037 | $11,900,614 | -$696,249 | $1.26 | 61 |
| 2023 Q4 | 9,848,515 | $17,531,878 | +$1,241,481 | $1.78 | 65 |
| 2023 Q3 | 9,166,276 | $15,209,597 | -$97,896 | $1.66 | 61 |
| 2023 Q2 | 8,974,519 | $17,902,094 | +$11,998,091 | $2.00 | 66 |
| 2023 Q1 | 2,937,638 | $6,146,705 | +$447,739 | $2.10 | 34 |
| 2022 Q4 | 3,567,822 | $4,870,646 | +$111,553 | $1.37 | 26 |
| 2022 Q3 | 3,548,189 | $3,696,081 | +$2,398,630 | $1.04 | 26 |
| 2022 Q2 | 1,193,025 | $1,298,298 | +$25,721 | $1.09 | 27 |
| 2022 Q1 | 1,217,014 | $1,287,936 | -$1,765,451 | $1.06 | 28 |
| 2021 Q4 | 2,921,778 | $2,436,675 | -$1,654,962 | $0.83 | 24 |
| 2021 Q3 | 4,412,957 | $5,908,463 | +$92,750 | $1.33 | 32 |
| 2021 Q2 | 4,315,299 | $8,240,101 | -$19,328,651 | $1.91 | 31 |
| 2021 Q1 | 8,821,889 | $39,349,366 | +$21,195,496 | $4.46 | 36 |
| 2020 Q4 | 4,087,703 | $14,838,993 | -$3,209,332 | $3.63 | 22 |
| 2020 Q3 | 4,761,719 | $18,443,257 | -$1,925,407 | $3.87 | 23 |
| 2020 Q2 | 5,260,461 | $19,818,169 | -$2,815,871 | $3.79 | 26 |